Defendant
1 case as defendant.
Ascletis Pharma China Co Ltd, often referred to as Ascletis Pharma Inc., is a biopharmaceutical company headquartered in Hangzhou, China, with operations also in Shaoxing, Zhejiang Province. Founded in 2011 by Jinzi Jason Wu, it is a publicly traded company listed on the Hong Kong Stock Exchange under the ticker 1672.HK. As of 2026, Ascletis Pharma Inc. reported approximately 202 employees and a market capitalization of $2.31 billion, with a trailing 12-month revenue of $282,000 as of December 31, 2025. The company's legal registration is in the Cayman Islands.
Ascletis is a fully integrated biotechnology company focused on the discovery, development, manufacturing, and commercialization of therapeutics. The company initially focused on antiviral drug development for conditions like hepatitis C (HCV) and HIV. More recently, it has expanded its focus to metabolic diseases, particularly obesity and cardiometabolic conditions, as well as immune diseases and oncology. Ascletis leverages proprietary technologies such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) for its drug candidates, which include small molecules and peptides. Its commercial products include Ritonavir tablets, GANOVO®, and ASCLEVIR®.
In terms of patent litigation, Ascletis Pharma China Co Ltd appears to primarily operate as a defendant. The company has been involved in one tracked case as a defendant and zero as a plaintiff. This single case, CONJUPRO BIOTHERAPEUTICS, INC. v. Ascletis Pharma China Co Ltd, is a proceeding before the Patent Trial and Appeal Board (PTAB), indicating a challenge to patent validity rather than a typical infringement suit in a district court.
The notable case involving Ascletis Pharma China Co Ltd is the PTAB proceeding initiated by CONJUPRO BIOTHERAPEUTICS, INC. on June 20, 2025. This indicates that Ascletis is an operating company defending its intellectual property or challenging competitor patents at the administrative level, rather than asserting a portfolio as a non-practicing entity.
This post-grant review (PGR) case, PGR2025-00057, was filed by CONJUPRO BIOTHERAPEUTICS, INC. against Ascletis Pharma China Co Ltd at the PTAB concerning US patent 12234236.